Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Linezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.98 |
| ▸ | MAOA | P21397 | 7/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.98 |
| ▸ | SDHA | P31040 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | CALML3 | P27482 | 1/20 | 0.98 |
| ▸ | F10 | P00742 | 4/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linezolid SCHEMBL2280731 | 1.00 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL1561095 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL30638355 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2222512 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL7992562 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL30226927 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL374752 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5027 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5524444 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2277149 | 0.98 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105503764-B | Linezolid form B and its production and use | 江苏豪森药业集团有限公司 | 2017-09-19 | — | — | CN | claimed |
| CN-105524009-B | Linezolid form B preparation method | 江苏豪森药业集团有限公司 | 2017-09-19 | — | — | CN | claimed |
| CN-105524009-A | Preparation method of linezolid in type B crystal form | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD | 2016-04-27 | — | — | CN | claimed |
| CN-105503764-A | Linezolid crystal form B and preparation method and application thereof | JIANGSU HANSOH PHARMA GROUP CO LTD | 2016-04-20 | — | — | CN | claimed |
| US-20100204470-A1 | METHOD FOR SALT PREPARATION | SANDOZ AG | 2010-08-12 | — | — | US | claimed |
| EP-2145890-A2 | Crystallization of hydrohalides of pharmaceutical compounds | Sandoz AG (CH) | 2010-01-20 | — | — | EP | claimed |
| EP-2032521-A2 | NEW METHOD FOR SALT PREPARATION | Sandoz AG (CH) | 2009-03-11 | — | — | EP | claimed |
| WO-2008000418-A2 | NEW METHOD FOR SALT PREPARATION | SANDOZ AG (CH) | 2008-01-03 | — | — | WO | claimed |
| CN-105524009-B | Linezolid form B preparation method | 江苏豪森药业集团有限公司 | 2017-09-19 | — | — | CN | disclosed |
| CN-105503764-B | Linezolid form B and its production and use | 江苏豪森药业集团有限公司 | 2017-09-19 | — | — | CN | disclosed |
| CN-105524009-B | Linezolid form B preparation method | 江苏豪森药业集团有限公司 | 2017-09-19 | — | — | CN | disclosed |
| CN-105524009-A | Preparation method of linezolid in type B crystal form | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD | 2016-04-27 | — | — | CN | disclosed |
| CN-105524009-A | Preparation method of linezolid in type B crystal form | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD | 2016-04-27 | — | — | CN | disclosed |
| CN-105503764-A | Linezolid crystal form B and preparation method and application thereof | JIANGSU HANSOH PHARMA GROUP CO LTD | 2016-04-20 | — | — | CN | disclosed |
| EP-2145890-A2 | Crystallization of hydrohalides of pharmaceutical compounds | Sandoz AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| EP-2032521-B1 | NEW METHOD FOR SALT PREPARATION | SANDOZ AG (CH) | 2009-10-28 | — | — | EP | disclosed |
| EP-2033960-A2 | Linezolid crystalline hydrate form and linezolid salts | Dipharma Francis S.r.l. (IT) | 2009-03-11 | — | — | EP | disclosed |
| EP-2032521-A2 | NEW METHOD FOR SALT PREPARATION | Sandoz AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-20090062534-A1 | LINEZOLID CRYSTALLINE HYDRATE FORM AND LINEZOLID SALTS | DIPHARMA FRANCIS S.R.L. (IT) | 2009-03-05 | — | — | US | disclosed |
| WO-2008000418-A2 | NEW METHOD FOR SALT PREPARATION | SANDOZ AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062534-A1 | LINEZOLID CRYSTALLINE HYDRATE FORM AND LINEZOLID SALTS | CYP3A43, HELZ, CYP2C9 | MAOB 2808/4885MAOA 1908/4885PTGS1 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.